Navigation Links
Ben-Gurion University of the Negev professor awarded the 2010 Elkeles Prize for Cancer Research
Date:8/8/2010

BEER-SHEVA, ISRAEL, August 9, 2010 Ben-Gurion University of the Negev (BGU) Professor Ron N. Apte has been awarded the 2010 Samuel and Paula Elkeles Prize for Outstanding Scientist in the Field of Medicine.

Professor Apte is chairman of the Shraga Segal Department of Microbiology and Immunology and vice dean of the Basic Sciences division in the BGU Faculty of Health Sciences. He is also the Irving Sklar Chair in Endocrinology and Cancer and a member of the National Institute for Biotechnology in the Negev.

Apte's major field of research involves inflammation in malignant processes. Approximately 15 percent of cancers are connected to inflammation, which typically result in organs where chronic inflammation has occurred. For example, patients with Inflammatory Bowel Disease (IBD) are more prone to cancer than the general population.

The pioneering studies of Apte's group demonstrated the feasibility of intervening in malignant process by neutralizing inflammatory components in the "normal" microenvironment of a tumor. They also detailed the basic concepts underlying such treatment.

Inflammatory cells affect proliferation and invasiveness of malignant cells through the secretion of cytokines, which include Interleukin-1 (IL-1), the molecule that has been studied for years by Apte's group. The group has demonstrated the involvement of IL-1-mediated inflammation in tumor invasiveness and metastasis. IL-1 causes tumor expansion because it suppresses the immune system and nourishes a tumor's blood vessels. Apte's group treated tumor-bearing mice with a specific inhibitor of IL-1, known as the IL-1 receptor antagonist (IL-Ra), and succeeded in weakening the tumor's invasiveness.

IL-Ra, in its generic form Anakirna, is a medication that efficiently alleviates symptoms of patients suffering from rheumatoid arthritis, a chronic inflammatory disease.

Apte joined the BGU Faculty of Sciences in 1981 and has served two full terms as vice dean, as the vice dean of Student Affairs, and as the vice dean for Graduate Studies. Since 2008, he has been the vice dean for Basic Science Affairs.

Apte has been a member of the board of the European Cytokine Society since 1989 and has served on the board of its journal, "The European Cytokine Network". He was also president of the Israel Immunological Society from 1996 to 1998.

Apte has served as a charter member of the International Cancer Microenvironment Society (ICMS) and as an editorial board member of its journal "Cancer Microenvironment". Prof. Apte has published more than 80 papers in the fields of immunology, tumor biology and cytokine biology.


'/>"/>

Contact: Andrew Lavin
andrewlavin@alavin.com
516-353-2505
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Related biology news :

1. Ben-Gurion University of the Negev researchers identify risks of hypertension in young adults
2. FDA approves trial for type 1 diabetes treatment by Ben-Gurion U. and U. Colorado
3. Ben-Gurion U researchers isolate microalgal strain that could reduce cholesterol
4. Uniform method to interpret autism spectrum disorders is defined at Ben-Gurion University
5. Anti-inflammatory drugs (coxibs) interfere with aspirins clotting ability -- Ben-Gurion U.
6. Heartburn drugs deemed safe for fetuses according to Ben-Gurion University researchers
7. Ben-Gurion University Alzheimers researcher demonstrates specific immune response to vaccine
8. Ben-Gurion University of the Negev technology being developed for use in Jordan desalination plant
9. Ben-Gurion U. developing new computer techniques to analyze historic Hebrew and Arabic documents
10. 1 in 6 health workers wont report in flu pandemic -- study by Ben-Gurion U. researchers
11. Ben-Gurion U. researchers reveal connection between cancer and human evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. ... developer of innovative sensor-based diagnostic products, today announced the closing ... new and existing investors.  Proceeds from the financing will be ... , a hand-held device for detecting early-stage pressure ulcers. ... Ireland after receiving CE Mark approval. The device,s ...
(Date:1/7/2016)... NEW YORK , Jan. 7, 2016 ... as regional markets for biometric technologies and devices, identifying ... application market for various types of biometric devices. Includes ... report to: Identify newer markets and explore the ... of biometric devices. Examine each type of biometric technology, ...
(Date:1/7/2016)... , Jan. 7, 2016  A United States ... the first court in the country to interpret a ... lawsuit to go forward against the photo website Shutterfly ... BRIAN NORBERG vs. SHUTTERFLY, INC.; and ... plaintiff alleges that Shutterfly violates the Illinois Biometric Privacy ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... ... 2016 , ... Shimadzu Scientific Instruments will showcase several new ... poster sessions, and present on the analysis of mycotoxins and medical cannabis at ... 10 at the Georgia World Congress Center in Atlanta, Georgia. , Attendees ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... VANCOUVER, British Columbia and MENLO PARK, ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies, today announced that it will present at the ... on Monday, February 8, 2016 at 10:00 a.m. EST in ... Jeffrey Bacha , DelMar,s president and CEO, will provide an ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
Breaking Biology Technology: